Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
111
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | Health | Discussion on the EU Biotech Act, access to medicines, innovation, and Ireland's life sciences policy environment, including opportunities to strengthen research, development, manufacturing, and the competitiveness of… (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland’s National Life Sciences Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicine (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness, pharmaceutical manufacturing, and EU-level health emergency preparedness (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Trade | Geopolitical polices in relation to tariffs and Most Favoured Nation (MFN) pricing (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | EU Affairs | Ireland priorities for the Presidency of the Council of the European Union (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 19 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Taxation | Reform of R&D tax credit (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs and related geo-political issues related to the pharmaceutical industry and pricing of medicines globally (Public policy or programme) | 11 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Treatment of Amyloidosis and ATTR-CM M (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs on pharmaceutical manufacturing and supply of medicines to patients globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | PFAS restrictions (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Access to an antiviral medication for the treatment of COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Economic Development and Industry | Life Science Strategy and Industrial Policy (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 15 | On lobbying.ie |
| May–Aug 2024 | Pfizer | Health | Digital Policy and the Life Science Industry (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Taxation | Proposed changes to global taxation at the OECD and by the U.S. administration (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Exchange about the burden of sickle-cell disease in Europe and the Pfizer-supported call to action Shaping the Change for Sickle Cell Disease Patients in Europe and Beyond. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | EU Affairs | Urban Wastewater Treatment Directive (UWWTD) (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Migraine Summit (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Ireland's medicine reimbursement system and Budget funding for new medicines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2023 | Pfizer | Taxation | Proposed changes to global taxation at the OECD and by the U.S. administration (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 5 | On lobbying.ie |
| May–Aug 2023 | Pfizer | Health | Ireland's reimbursement system and funding for new medicines (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Taxation | Proposed changes to global taxation at the OECD and by the U.S. administration (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | Potential EU proposals to restrict use of titanium dioxide and PFAS in medicines (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Economic Development and Industry | Pfizer recent 1.2 billion euro investment in Ireland operations creating 400-500 jobs (Public policy or programme) | 13 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Health | Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) | 14 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 3 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | European System of Accounts (EU Accounting Rules) (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Health | Pfizer anti-viral COVID-19 treatment and COVID-19 cases (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Energy and Natural Resources | Potential energy shortages (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 7 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 56 | 50.5% | |
| EU Affairs | 21 | 18.9% | |
| Economic Development and Industry | 17 | 15.3% | |
| Taxation | 9 | 8.1% | |
| Trade | 4 | 3.6% | |
| Budgetary matters | 2 | 1.8% | |
| Energy and Natural Resources | 1 | 0.9% | |
| Transport | 1 | 0.9% |